Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
News18 » India
1-min read

Effective HIV vaccine comes closer to reality

The new findings point the way towards a potentially more effective vaccine that would generate V1V2 directed HIV neutralising antibodies, researchers said.

Press Trust Of India

Updated:March 3, 2014, 1:53 PM IST
facebookTwitter Pocket whatsapp
Effective HIV vaccine comes closer to reality
The new findings point the way towards a potentially more effective vaccine that would generate V1V2 directed HIV neutralising antibodies, researchers said.

Washington: Scientific have discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a key site, paving way for an effective vaccine for the deadly virus.

Researchers believe that if a vaccine could elicit potent antibodies to a specific conserved site in the V1V2 region of the virus, one of a handful of sites that remains constant on the fast-mutating virus, then the vaccine could protect people from HIV infection.

Analyses of the results of a clinical trial of the only experimental HIV vaccine to date to have modest success in people suggest that antibodies to sites within V1V2 were protective.

The new findings point the way towards a potentially more effective vaccine that would generate V1V2 directed HIV neutralising antibodies, researchers said. The study led by the National Institute of Allergy and Infectious Diseases (NIAID) scientists began by identifying an HIV-infected volunteer who naturally developed V1V2-directed HIV neutralising antibodies, named CAP256-VRC26, after several months of infection.

Using techniques similar to those employed in an earlier study of HIV-antibody co-evolution, the researchers analysed blood samples donated by the volunteer between 15 weeks and 4 years after becoming infected.

This enabled the scientists to determine the genetic make-up of the original form of the antibody; to identify and define the structures of a number of the intermediate forms taken as the antibody mutated towards its fullest breadth and potency.

It also allowed them to describe the interplay between virus and antibody that fostered the maturation of CAP256-VRC26 to its final, most powerful HIV-fighting form. The study showed that after relatively few mutations, even the early intermediates of CAP256-VRC26 can neutralise a significant proportion of known HIV strains.

This improves the chances that a V1V2-directed HIV vaccine developed based on the new findings would be effective, according to scientists, who have begun work on a set of vaccine components designed to elicit V1V2 neutralising antibodies and guide their maturation.

Support the daily wage earners who have been hit the hardest by the COVID-19 crisis. Click here to contribute to the cause. #IndiaGives

The daily News18 Coronavirus COVID-19 newsletter - Get your copy here.

Subscribe to News18 Daybreak. Follow us on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube

Read full article

Live TV

Countdown To Elections Results
To Assembly Elections 2018 Results

India

  • Active Cases

    3,666

     
  • Total Confirmed

    4,067

     
  • Cured/Discharged

    291

     
  • Total DEATHS

    109

     
Data Source: Ministry of Health and Family Welfare, India
Updated: April 06 (09:00 AM)
Hospitals & Testing centres

World

  • Active Cases

    944,388

     
  • Total Confirmed

    1,286,717

     
  • Cured/Discharged

    271,882

     
  • Total DEATHS

    70,447

     
Data Source: Johns Hopkins University, U.S. (www.jhu.edu)
Hospitals & Testing centres